EP3400007A1 - Orthomyxo-like virus of tilapia - Google Patents
Orthomyxo-like virus of tilapiaInfo
- Publication number
- EP3400007A1 EP3400007A1 EP17735934.6A EP17735934A EP3400007A1 EP 3400007 A1 EP3400007 A1 EP 3400007A1 EP 17735934 A EP17735934 A EP 17735934A EP 3400007 A1 EP3400007 A1 EP 3400007A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- tlv
- nos
- isolated
- tilapia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 88
- 241000276707 Tilapia Species 0.000 title claims description 72
- 230000002238 attenuated effect Effects 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical group 0.000 claims description 67
- 102000039446 nucleic acids Human genes 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 50
- 239000002299 complementary DNA Substances 0.000 claims description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 230000003321 amplification Effects 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- -1 radioactive label Substances 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 9
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 241000465502 Tobacco latent virus Species 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 abstract description 40
- 229960005486 vaccine Drugs 0.000 abstract description 32
- 238000001514 detection method Methods 0.000 abstract description 16
- 238000012512 characterization method Methods 0.000 abstract description 11
- 238000002955 isolation Methods 0.000 abstract description 6
- 241001493065 dsRNA viruses Species 0.000 abstract description 5
- 239000013615 primer Substances 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 40
- 239000000523 sample Substances 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 238000013519 translation Methods 0.000 description 24
- 230000014616 translation Effects 0.000 description 24
- 230000002441 reversible effect Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 230000000120 cytopathologic effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000003463 organelle Anatomy 0.000 description 5
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 241000712464 Orthomyxoviridae Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000005081 chemiluminescent agent Substances 0.000 description 3
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 2
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 241000276703 Oreochromis niloticus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- DUFUXAHBRPMOFG-UHFFFAOYSA-N 1-(4-anilinonaphthalen-1-yl)pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C1=CC=CC=C11)=CC=C1NC1=CC=CC=C1 DUFUXAHBRPMOFG-UHFFFAOYSA-N 0.000 description 1
- ZTTARJIAPRWUHH-UHFFFAOYSA-N 1-isothiocyanatoacridine Chemical compound C1=CC=C2C=C3C(N=C=S)=CC=CC3=NC2=C1 ZTTARJIAPRWUHH-UHFFFAOYSA-N 0.000 description 1
- RUDINRUXCKIXAJ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosafluorotetradecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RUDINRUXCKIXAJ-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
- YJCCSLGGODRWKK-NSCUHMNNSA-N 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulphonic acid Chemical compound OS(=O)(=O)C1=CC(NC(=O)C)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YJCCSLGGODRWKK-NSCUHMNNSA-N 0.000 description 1
- OSWZKAVBSQAVFI-UHFFFAOYSA-N 4-[(4-isothiocyanatophenyl)diazenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N=C=S)C=C1 OSWZKAVBSQAVFI-UHFFFAOYSA-N 0.000 description 1
- ZWONWYNZSWOYQC-UHFFFAOYSA-N 5-benzamido-3-[[5-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C(N=NC2=CC(NC3=NC(NC4=CC=C(C=C4)S(O)(=O)=O)=NC(Cl)=N3)=CC=C2S(O)(=O)=O)C(=CC2=C1C(NC(=O)C1=CC=CC=C1)=CC(=C2)S(O)(=O)=O)S(O)(=O)=O ZWONWYNZSWOYQC-UHFFFAOYSA-N 0.000 description 1
- YERWMQJEYUIJBO-UHFFFAOYSA-N 5-chlorosulfonyl-2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]benzenesulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(Cl)(=O)=O)C=C1S([O-])(=O)=O YERWMQJEYUIJBO-UHFFFAOYSA-N 0.000 description 1
- AXGKYURDYTXCAG-UHFFFAOYSA-N 5-isothiocyanato-2-[2-(4-isothiocyanato-2-sulfophenyl)ethyl]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1CCC1=CC=C(N=C=S)C=C1S(O)(=O)=O AXGKYURDYTXCAG-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- TXSWURLNYUQATR-UHFFFAOYSA-N 6-amino-2-(3-ethenylsulfonylphenyl)-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1C1=CC=CC(S(=O)(=O)C=C)=C1 TXSWURLNYUQATR-UHFFFAOYSA-N 0.000 description 1
- YALJZNKPECPZAS-UHFFFAOYSA-N 7-(diethylamino)-3-(4-isothiocyanatophenyl)-4-methylchromen-2-one Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C1=CC=C(N=C=S)C=C1 YALJZNKPECPZAS-UHFFFAOYSA-N 0.000 description 1
- SGAOZXGJGQEBHA-UHFFFAOYSA-N 82344-98-7 Chemical compound C1CCN2CCCC(C=C3C4(OC(C5=CC(=CC=C54)N=C=S)=O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 SGAOZXGJGQEBHA-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000736160 Cynoscion regalis Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 101100168115 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-6 gene Proteins 0.000 description 1
- 241000647380 Oreochromis sp. YCC-2008 Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101150036912 Segment-5 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241001492212 Striped Jack nervous necrosis virus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
- 241001601305 Tilapia lake virus Species 0.000 description 1
- 241001417488 Tilapia sp. Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- KPBGWWXVWRSIAY-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-6-isothiocyanato-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=C(N=C=S)C=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KPBGWWXVWRSIAY-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XHXYXYGSUXANME-UHFFFAOYSA-N eosin 5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 XHXYXYGSUXANME-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- AJMSJNPWXJCWOK-UHFFFAOYSA-N pyren-1-yl butanoate Chemical compound C1=C2C(OC(=O)CCC)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 AJMSJNPWXJCWOK-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- This disclosure relates to isolation and characterization of a newly-discovered RNA virus of fish. Also disclosed are methods for detection of the isolated virus, a live attenuated virus vaccine, and an inactivated virus vaccine.
- Tilapia is the common name for approximately hundred species of tropical chiclid fish which globally are the second most cultivated food fish following carp. Based on reports from the Food and Agriculture association of the United Nations (FAO), the Nile tilapia, Oreochromis niloticus, is the one of the major tilapia species cultivated for consumption, reaching a global production of 3.2 million tons (mt) in 2012 (FAO). Tilapia sp. is cultured in warm climate countries, with Israel being one of its most northern points of distribution.
- the identified parasites varied by species and therefore could not account for the epizootic events. Moreover, it is known that such parasites can be a secondary pathogen, and not the primary cause of mortality. No significant correlation was seen for presence of bacteria and mortality events. Additionally, the onset of disease and clinical signs were not characteristic of known viral pathogens of Tilapia.
- TLV Tilapia Virus
- isolated orthomyxo-like viruses having a genome comprised of nucleic acid sequences at least 90% identical to each of SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, and 24.
- nucleic acids comprising a nucleic acid at least 90% identical to a nucleic acid selected from the group consisting of SEQ ID NOs 25-48.
- the present disclosure also describes methods for detecting a Tilapia virus (TLV) infection, which include isolating a sample from a subject suspected of being infected by TLV; generating a cDNA template from the sample; and amplifying a nucleic acid from the cDNA template using at least one oligonucleotide primer comprising a nucleic acid sequence at least 90% identical to at least one sequence selected from the group consisting of SEQ ID Nos: 25- 48, wherein amplification of a nucleic acid sequence with the primer indicates the presence of TLV in the sample.
- TLV Tilapia virus
- TLV Tilapia viruses
- kits for detecting TLV which include the described nucleic acids, and methods of vaccinating a subject against TLV through use of the isolated inactivated or attenuated viruses.
- Figure 1 is an electron micrograph (EM) of infected tilapia cells at day 5 postinfection. Cells exhibit disintegration of cellular compartments and organelles. Cytoplasmic vacuoles contain an abundance of virus like structures varying in size and morphology (arrows, right panel).
- EM electron micrograph
- FIG. 2 shows non-infected (top panel) and infected (bottom panel) Tilapia fin cells
- TFC maintained at 15°C-33°C.
- Infected cells at 15°C exhibit normal morphology with no apparent CPE.
- At 23°C-33°C cells exhibit cytoplasmic vacuolization and rounding of cells which eventually causes mortality of the cell culture.
- Figure 3 is a phylogenic analysis of contig 4 of TLV resembling the PB1 RNA Polymerase of Orthomyxo virus. Using TREX-MAFFT sequence alignment software a Phylogenic tree was assembled, comparing known Orthomyxo virus PB1 amino acid sequences to that of TLV.
- FIG. 4 is a chart showing the generation of mutation in TLV through sub lethal irradiation.
- TLV was irradiated at increasing dosages of UV and the residual infectivity was determined by viral titration on 96 microwell plates, as shown in the chart. At the highest dosage where residual infectivity was maintained viral clones were picked and propagated.
- Figure 5 is a chart showing the safety profile of two attenuated TLV clones compared to a placebo treated group.
- Figure 6 is a chart showing the efficacy of vaccine prototypes when challenged with a lethal dose of wildtype TLV by IP injection.
- Figure 7 is an electrophoresis gel showing detection of TLV using Conl9 primers, in infected cultures and demonstrating that TLV has an RNA genome that does not pass through a DNA stage during its propagation cycle. Specificity of Conl9 as a viral contig. Conl9 primers (lanes 1-5) or Endogenous tilapia control TL-NA primers (lane 6-10) were assayed using either DNA or RNA extracted from infected and non-infected TFC. RNA was used to generate total cDNA using Aurum Total RNA Mini kit (BIO-RAD Cat# 732-6820).
- Figure 8 is an electrophoresis gel showing use of Con4 as a diagnostic tool to identify
- TLV from infected fish TLV is readily identified in both experimentally infected fish as in field epizootics.
- RNA was extracted from fish brains and served as template for RT-PCR using Con4 primers (top pane) or a Tilapia endogenous marker (TL-NA) as control (bottom pane).
- Lane 21 -Healthy fish collected from the same farm.
- Figure 9 is a graph showing accumulated mortality of Tilapia fish challenged through IP injection with virulent TLV when vaccinated with inactivated TLV preparations as shown in the figure. Accumulated mortality of Tilapia fish challenged through IP injection with virulent TLV, 28 days post IP vaccination with: x - Medium from uninfected TFC cells, x - Naive fish, ⁇ - Formalin inactivated TLV in emulsion with Freund's incomplete adjuvant - IFA (1: 1), 0 - Formalin inactivated TLV, and O - emulsion containing Placebo - Medium from uninfected cells with Freund's incomplete adjuvant - IFA (1: 1).
- nucleic and/or amino acid sequences provided herewith are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. As described herein:
- SEQ ID NO: 1 is the sequence of Contig 4.
- SEQ ID NO: 2 is the conceptual translation of Contig 4.
- SEQ ID NO: 3 is the sequence of Contig 7.
- SEQ ID NO: 4 is the conceptual translation of Contig 7.
- SEQ ID NO: 5 is the sequence of Contig 5.
- SEQ ID NO: 6 is the conceptual translation of Contig 5.
- SEQ ID NO: 7 is the sequence of Contig 6.
- SEQ ID NO: 8 is the conceptual translation of Contig 6.
- SEQ ID NO: 9 is the sequence of Contig 8.
- SEQ ID NO: 10 is the conceptual translation of Contig 8.
- SEQ ID NO: 11 is the sequence of Contig 14.
- SEQ ID NO: 12 is the conceptual translation of Contig 14.
- SEQ ID NO: 13 is the sequence of Contig 15.
- SEQ ID NO: 14 is the conceptual translation of Contig 15.
- SEQ ID NO: 15 is the sequence of Contig 12.
- SEQ ID NO: 16 is the conceptual translation of Contig 12.
- SEQ ID NO: 17 is the sequence of Contig 16.
- SEQ ID NO: 18 is the conceptual translation of Contig 16
- SEQ ID NO: 19 is the sequence of Contig 20.
- SEQ ID NO: 20 is the conceptual phase 1 translation of Contig 20.
- SEQ ID NO: 21 is the conceptual phase 2 translation of Contig 20.
- SEQ ID NO: 22 is the sequence of Contig 21.
- SEQ ID NO: 23 is the conceptual translation of Contig 21.
- SEQ ID NO: 24 is the sequence of Contig 19.
- SEQ ID Nos. 25 and 26 are respective forward and reverse primers specific to Contig 4.
- SEQ ID Nos. 27 and 28 are respective forward and reverse primers specific to Contig 7.
- SEQ ID Nos. 29 and 30 are respective forward and reverse primers specific to Contig 5.
- SEQ ID Nos. 31 and 32 are respective forward and reverse primers specific to Contig 6.
- SEQ ID Nos. 33 and 34 are respective forward and reverse primers specific to Contig 8.
- SEQ ID Nos. 35 and 36 are respective forward and reverse primers specific to Contig 14.
- SEQ ID Nos. 37 and 38 are respective forward and reverse primers specific to Contig 15.
- SEQ ID Nos. 39 and 40 are respective forward and reverse primers specific to Contig 12.
- SEQ ID Nos. 41 and 42 are respective forward and reverse primers specific to Contie 16.
- SEQ ID Nos. 43 and 44 are respective forward and reverse primers specific to
- SEQ ID Nos. 45 and 46 are respective forward and reverse primers specific to
- SEQ ID Nos. 47 and 48 are respective forward and reverse primers specific to
- SEQ ID NO: 49 is a mutated segment 4 sequence from an attenuated TLV.
- SEQ ID NO: 50 is a mutated segment 5 sequence from an attenuated TLV.
- Administration The introduction of a composition into a subject by a chosen route.
- Administration of an active compound or composition can be by any route known to one of skill in the art.
- Administration can be local or systemic.
- Amplification When used in reference to a nucleic acid, any technique that increases the number of copies of a nucleic acid molecule in a sample or specimen. An example of amplification is the polymerase chain reaction (PCR), in all of its currently practiced variations, in which a biological sample collected from a subject is contacted with a pair of oligonucleotide primers, under conditions that allow for the hybridization of the primers to nucleic acid template in the sample.
- PCR polymerase chain reaction
- the primers are extended under suitable conditions, dissociated from the template, and then re-annealed, extended, and dissociated to amplify the number of copies of the nucleic acid.
- the product of in vitro amplification can be characterized by electrophoresis, restriction endonuclease cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic acid sequencing, using standard techniques.
- Non- limiting examples of PCR include RT-PCR and qPCR.
- Other examples of in vitro amplification techniques include strand displacement amplification (see U.S. Patent No. 5,744,311); transcription-free isothermal amplification (see U.S. Patent No.
- Animal Living multi-cellular vertebrate organisms, a category that includes for example, fish, mammals and birds.
- mammal includes both human and non-human mammals.
- subject includes both human and veterinary subjects, for example, humans, non-human primates, fish, dogs, cats, horses, and cows.
- subject includes both human and veterinary subjects, such as fish.
- Attenuated virus a virus that has been altered in order to reduce or eliminate its virulence. Attenuated viruses are "live", but have a reduced or eliminated ability to damage or kill host cells, and therefore cause a virus -associated pathology.
- Biological Sample Any sample that may be obtained directly or indirectly from an organism, including whole blood, plasma, serum, tears, mucus, saliva, urine, pleural fluid, spinal fluid, gastric fluid, sweat, semen, vaginal secretion, sputum, fluid from ulcers and/or other surface eruptions, blisters, abscesses, tissues, cells (such as, fibroblasts, peripheral blood mononuclear cells, or muscle cells), organelles (such as mitochondria), organs, and/or extracts of tissues, cells (such as, fibroblasts, peripheral blood mononuclear cells, or muscle cells), organelles (such as mitochondria) or organs.
- a biological sample may also be a laboratory research sample such as a cell culture supernatant. The sample is collected or obtained using methods well known to those skilled in the art. In the current disclosure, "biological sample” is used interchangeably with “sample.”
- cDNA complementary DNA: A piece of DNA lacking internal, non-coding segments (introns) and transcriptional regulatory sequences. cDNA can also contain untranslated regions (UTRs) that are responsible for translational control in the corresponding
- RNA molecule RNA molecule. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.
- a double- stranded DNA or RNA strand consists of two complementary strands of base pairs. Complementary binding occurs when the base of one nucleic acid molecule forms a hydrogen bond to the base of another nucleic acid molecule.
- the base adenine (A) is complementary to thymidine (T) and uracil (U), while cytosine (C) is complementary to guanine (G).
- T thymidine
- U uracil
- G guanine
- the sequence 5'-ATCG-3' of one ssDNA molecule can bond to 3'-TAGC-5' of another ssDNA to form a dsDNA.
- the sequence 5'-ATCG-3' is the reverse complement of 3'-TAGC-5'.
- cDNA produced from an ssRNA molecule will be the reverse complement of the RNA sequence.
- Contacting Placement in direct physical association. Includes both in solid and liquid form. Contacting can occur in vitro with isolated cells or in vivo by administering to a subject.
- Detect To determine if an agent (such as a signal or particular nucleotide nucleic acid probe, amino acid, or protein, for example a TLV protein or nucleic acid) is present or absent. In some examples, this can further include quantification.
- an agent such as a signal or particular nucleotide nucleic acid probe, amino acid, or protein, for example a TLV protein or nucleic acid
- Diagnosis The process of identifying a disease, by its signs, symptoms, and results of various tests and methods, for example the methods disclosed herein.
- Fluorophore A chemical compound, which when excited by exposure to a particular stimulus, such as a defined wavelength of light, emits light (fluoresces), for example at a different wavelength (such as a longer wavelength of light).
- Fluorophores are part of the larger class of luminescent compounds.
- Luminescent compounds include chemiluminescent molecules, which do not require a particular wavelength of light to luminesce, but rather use a chemical source of energy. Therefore, the use of chemiluminescent molecules (such as aequorin) can eliminate the need for an external source of electromagnetic radiation, such as a laser. Examples of particular fluorophores that can be used in the probes and primers disclosed herein are provided in U.S. Patent No.
- Inactivated virus a virus that has been inactivated or "killed” in order to eliminate its virulence. Although not infectious, inactivated virus particles can provoke an immune response, and can form the basis of a vaccine.
- Non-limiting methods of viral inactivation include heat, UV exposure, or chemical means, such as exposure to formaldehyde (formalin).
- Isolated A biological component (such as a nucleic acid molecule, protein or organelle) that has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles.
- Nucleic acids and proteins that have been isolated include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
- Label A detectable compound or composition that is conjugated directly or indirectly to another molecule to facilitate detection of that molecule.
- Specific, non-limiting examples of labels include radioactive isotopes (such as S 35 and P 32 ), enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes.
- Oligonucleotide A plurality of joined nucleotides joined by native phosphodiester bonds, between about 6 and about 300 nucleotides in length.
- An oligonucleotide analog refers to moieties that function similarly to oligonucleotides but have non-naturally occurring portions.
- Particular oligonucleotides and oligonucleotide analogs can include linear sequences up to about 300 nucleotides in length, for example a sequence (such as DNA or RNA) that is at least 6 bases, for example at least 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or even 200 or 300 bases long, or from about 6 to about 50 bases, for example about 10-25 bases, such as 12, 15 or 20 bases.
- Orthomyxoviridae An RNA virus family, which includes influenza virus.
- Orthomyxoviridae can have filamentous or spherical capsids. Their RNA genome is segmented and is transcribed and replicated by virus-encoded RNA dependent RNA polymerases.
- Nucleic acid probes and primers can be readily prepared based on the nucleic acid molecules provided in this invention.
- a probe comprises an isolated nucleic acid attached to a detectable label or reporter molecule.
- Typical labels include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes.
- Primers are short nucleic acid molecules, preferably DNA oligonucleotides 10 nucleotides or more in length. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then the primer extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the PCR or other nucleic-acid amplification methods known in the art.
- purified does not require absolute purity; rather, it is intended as a relative term.
- a purified protein preparation is one in which the protein referred to is more pure than the protein in its natural environment within a cell.
- Quantitative real time PCR A method for detecting and measuring products generated during each cycle of a PCR, which products are proportionate to the amount of template nucleic acid present prior to the start of PCR.
- the information obtained, such as an amplification curve, can be used to quantitate the initial amounts of template nucleic acid sequence.
- Sequence identity The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are.
- Vaccine a composition that induces a subject to acquire immunity protective against a specific disease-causing agent (pathogen), such as a virus or bacteria.
- pathogen a specific disease-causing agent
- Vaccines can include, inter alia, antigenic fragments of the pathogen, which in turn induce the immune response in the subject.
- Other vaccine examples include live attenuated or killed vaccines in which the pathogen itself is the basis for the vaccine.
- the vaccine described herein is a live attenuated TLV strain.
- Vaccination is the process of providing a vaccine, and thereby protection, to a subject against a pathogen.
- a vaccine is an exemplary type of immunogenic composition.
- Virus Microscopic infectious organism that reproduces inside living cells.
- a virus consists essentially of a core of a single nucleic acid surrounded by a protein coat, and has the ability to replicate only inside a living cell.
- "Viral replication" is the production of additional virus by the occurrence of at least one viral life cycle.
- a virus may subvert the host cells' normal functions, causing the cell to behave in a manner determined by the virus. For example, a viral infection may result in a cell producing a cytokine, or responding to a cytokine, when the uninfected cell does not normally do so.
- Virion A complete viral particle including envelope, capsid, and nucleic acid elements.
- TLV Tilapia Virus
- isolated orthomyxo-like viruses having a genome comprised of nucleic acid sequences at least 90% identical to each of SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, and 24.
- nucleic acids comprising a nucleic acid at least 90% identical to a nucleic acid selected from the group consisting of SEQ ID NOs 25-48.
- the nucleic acid further comprises a detectable label, such as a fluorescent label, radioactive label, or chemical label.
- the present disclosure also describes methods for detecting a Tilapia virus (TLV) infection, which include isolating a sample from a subject suspected of being infected by TLV; generating a cDNA template from the sample; and amplifying a nucleic acid from the cDNA template using at least one oligonucleotide primer comprising a nucleic acid sequence at least 90% identical to at least one sequence selected from the group consisting of SEQ ID Nos: 25- 48, wherein amplification of a nucleic acid sequence with the primer indicates the presence of TLV in the sample.
- TLV Tilapia virus
- the amplifying is carried out with at least one primer pair having sequences at least 90% to the primer pairs selected from the group consisting of SEQ ID NOs 25 and 26; SEQ ID NOs 27 and 28; SEQ ID NOs 29 and 30; SEQ ID NOs 31 and 32; SEQ ID NOs 33 and 34; SEQ ID NOs 35 and 36; SEQ ID NOs 37 and 38; SEQ ID NOs 39 and 40; SEQ ID NOs 41 and 42; SEQ ID NOs 43 and 44; SEQ ID NOs 45 and 46; and SEQ ID NOs 47 and 48.
- kits for detecting a Tilapia virus (TLV) infection which contain at least one of the described isolated nucleic acids.
- kits contain at least one isolated nucleic acid which is at least one oligonucleotide primer pair having sequences at least 90% identical to the primer pairs selected from the group consisting of SEQ ID NOs 25 and 26; SEQ ID NOs 27 and 28; SEQ ID NOs 29 and 30; SEQ ID NOs 31 and 32; SEQ ID NOs 33 and 34; SEQ ID NOs 35 and 36; SEQ ID NOs 37 and 38; SEQ ID NOs 39 and 40; SEQ ID NOs 41 and 42; SEQ ID NOs 43 and 44; SEQ ID NOs 45 and 46; and SEQ ID NOs 47 and 48.
- kits further include detectable label, which in particular embodiments can be associated with at least one of the isolated nucleic acids in the kit.
- detectable label in particular embodiments can be associated with at least one of the isolated nucleic acids in the kit.
- Isolated attenuated and isolated inactivated Tilapia viruses are also described herein.
- an isolated attenuated Tilapia virus produced by the process of passaging the TLV through tilapia cells at least 10 times, irradiating the TLV at a sublethal radiation dose; and isolating an infectious attenuated clone.
- the isolated attenuated TLV is passaged at least 20 times through tilapia cells.
- the sublethal radiation dose is between 3.2-6.8 mJ/cm 2 , such as 6.8 mJ/cm 2 .
- An exemplary isolated attenuated TLV provided herein was deposited with the CNCM (Pasteur Institute) as Accession No. CNCM 1-5075.
- the isolated attenuated or inactivated TLV strains described herein are part of an immunogenic composition, such as a compositions that also include an adjuvant.
- the present disclosure additionally describes methods for vaccinating a subject against a Tilapia virus (TLV) infection.
- TLV Tilapia virus
- such vaccination includes infecting a subject with the described isolated attenuated or inactivated TLVs.
- vaccination includes administering to a subject an immunogenic composition comprising the described isolated attenuated or inactivated TLVs.
- TLV Tilapia Virus
- TLV Primary characterization of TLV indicates a spherical, pleomorphic RNA virus, which propagates in a temperature dependent manner between 23°C-33°C. Virus has been grown to a high titer and deposited on June 15, 2014 at the CNCM (Pasteur Institute) under Accession No. CNCM 1-4892.
- TLV contig 4 (set our herein as SEQ NO: 1) includes a putative conserved domain of the Influenza RNA- dependent RNA polymerase subunit PB 1.
- Contiguous (contig) sequences have been determined from TLV, set out herein as SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, and 24.
- the described TLV contains a genome having an identical sequence to those sequences set forth as SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, and 24. It is appreciated however that genomic variation from the described TLV sequences will exist in different isolated TLV. Accordingly, in particular embodiments, the isolated TLV described herein has a genome in which any one of the contigs can be less than 100% identical to the sequences set out as SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, and 24. Such sequences may be at least 99%, 95%, 90%, 85%, 80% or even less identical to one or more of the described contig sequences.
- the isolated genomic sequences can be synthetically produced as described or as DNA (e.g. cDNA) or as shorter RNA or DNA fragments of the sequences described herein.
- Non- limited uses of such fragments include probes and primers for use in any method known to the art for detection of the virus in a sample.
- the fragments (which can be probes) can be least 99%, 95%, 90%, 85%, 80%, 75%, 70% or even less identical to the reverse complement of the contig sequence to be detected.
- an isolated probe for use in detecting TLV can be 95%, 90%, 85%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, any percentage in between, or even less in length compared with the sequence to be detected.
- contig 4 is 1620 nucleotides (nt) long.
- a described isolated probe of contig 4 can therefore be identical to the sequence of SEQ ID NO: l, but can be significantly shorter in length, such as 1600, 1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50 nt long, or any length in between.
- an isolated nucleic acid that can be used as a probe for contig 4 (SEQ ID NO: 1) can be 35- 1620 nt long, such as 50- 1600 nt, 1000- 1600 nt, 500- 1500 nt, 750- 1200 nt, and any length in between.
- isolated nucleic acid fragments, including DNA or RNA fragments, of each of the contig sequences can similarly be used as a used as a probe sequence for the individual contig.
- sequences set out as SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 22, and 24, or any shorter inclusive sequence can be amplified as described herein using primers developed from the described sequences.
- the primers can be 12-35 nt long, such as 15-25 nt, 18-30 nt and the like.
- primers that can be used to amplify the described sequences include the oligonucleotide primers set forth herein as SEQ ID NOs 25-48, or primers at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or even more identical to SEQ ID NOs 25-48.
- the isolated nucleic acid sequences set out as SEQ ID NOs. 1, 3, 5, 7, 9, 1 1, 13, 15, 17, 19, 22, and 24, and fragments thereof (including probes and primers), can be covalently modified to include a detectable label as described herein.
- detectable label include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes.
- the label is a radioactive label.
- the label is a fluorescent label, such as any one of the fluorescent labels described herein.
- a sample such as a sample collected from a subject (e.g. a Tilapia fish).
- the methods include detecting a TLV nucleic acid in the sample, which indicates the presence of TLV in the sample.
- the sample is isolated from an individual subject, such as a Tilapia fish.
- the sample is collected from a population, such as a population of fish.
- the sample is collected from an environment in which subjects live, such as fish pond and the like.
- the sample is a sample from one or more subjects, the presence of a TLV nucleic acid or protein in the sample indicates that the subject is infected by TLV.
- the labeled probes or primers described herein can be used to detect TLV in a sample by standard hybridization techniques, including in an array, such as a microarray.
- Other methods of detection include any suitable method of nucleic acid amplification, such as PCR and its variations including RT-PCR and qPCR.
- TLV has an RNA genome that does not pass through a
- kits for detecting TLV in a sample include at least one of the TLV-specific probes and primers described above.
- the kits include reagents for isolating viral RNA from a sample.
- the kits include reagents and/or enzymes for reverse transcription and DNA amplification.
- the kits include at least one primer pair such as respective pairs from the oligonucleotides set forth herein as SEQ ID NOs 25-48, or primers at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or even more identical to SEQ ID NOs 25-48.
- the supplied TLV-specific nucleic acids are pre-labeled with a detectable label.
- a detectable label is included in the kit along with optional reagents and/or enzymes for associating the label with the nucleic acid.
- TLV isolates which can confer resistance to wildtype TLV infection.
- the attenuated viruses provided herein are isolated and cloned following multiple passages through Tilapia cells, followed by exposure to a non-lethal mutagenic condition, such as ultraviolet radiation or chemical mutagen.
- the attenuated TLV strain is produced by first passaging the virus, by methods known in the art (e.g. wherein each passage is a cycle of infection and isolation of virus resultant from the infection), at least 10 times through Tilapia cells, such as
- each passage is followed by exposure to a mutagenic condition prior to the next passage cycle.
- a non-lethal (also described herein as "sublethal") mutagenic condition e.g. a condition wherein the virus may continue to infect cells
- UV radiation such as 3.2-6.8 mJ/cm 2 , and more particularly 6.8 mJ/cm 2 .
- an attenuated TLV strain is produced by passaging wildtype TLV through Tilapia Fin Cells for 20 passages, exposing the cells to a UV radiation dose of 6.8 mJ/cm 2 , and then isolating an individual virus clone.
- the described attenuated TLV strain can confer partial or complete resistance to TLV infection such that a population of vaccinated fish that is challenged by wildtype TLV will show at least a 60% survival rate, such as 60%-100% survival, such as 70%, 80%, 85%, 90%, 95%, 95%-
- a particular example of an attenuated TLV as described herein is the attenuated TLV that has been deposited with the CNCM (Pasteur Institute) on April 1, 2016 as Accession No. CNCM 1-5075.
- Inactivated (killed) virus immunogenic compositions can be produced according to methods known in the art, including incubation with formalin as described herein.
- the attenuated and/or inactivated TLV isolates is a component of an immunogenic composition (e.g. a TLV vaccine) that includes the attenuated and/or inactivated virus, a pharmaceutically acceptable carrier and optionally one or more adjuvants or other immune-stimulating agents.
- an immunogenic composition e.g. a TLV vaccine
- the pharmaceutically acceptable carrier can be water or a buffer, or additionally a composition stabilizer.
- the vaccines are prepared as liquid solutions, emulsions or suspensions for injection.
- delivery can be through immersion of fish in water.
- a liquid emulsion or emulsifiable concentrate can be prepared for addition to water where fish are held.
- Solid (e.g. powder) forms suitable for dissolution in, or suspension in, liquid vehicles or for mixing with solid food, prior to administration can also be prepared.
- the vaccine may be a lyophilized culture for reconstitution with a sterile diluent. For example 0.9% saline.
- a variety of ingredients may be added to the vaccine such as preservatives, antioxidants or reducing agents, a variety of excipients, etc. Such excipients may also be added to the dry virus after the drying step.
- the immunogenic composition includes an adjuvant or other immune stimulant.
- adjuvants are well known to the art. Particular non-limiting examples include muramyl dipeptides, avidine, aluminium hydroxide, aluminium phosphate, oils, oil emulsions, saponins, dextran sulphate, glucans, cytokines, block co-polymers, immuno stimulatory oligonucleotides and others known in the art may be admixed with the attenuated and/or inactivated TLV.
- the described immunogenic composition additionally comprises at least one stabilizer to protect it from degradation, to enhance the shelf-life, or to improve freeze-drying efficiency.
- stabilizers for use with the described vaccine include SPGA (Bovarnik et al., 1950, J. Bacteriology, vol. 59, p. 509), skimmed milk, gelatin, bovine serum albumin, carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, lactoses, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.
- the described attenuated and/or inactivated TLV immunogenic composition can be used in methods of vaccination against TLV by infecting at least one subject with the attenuated TLV vaccine described herein and/or exposing the subject to the inactivated TLV.
- the vaccine is administered to fish individually-orally, such as through their feed or by forced oral administration, or by injection, such as via the intramuscular or intraperitoneal route
- the vaccine can be administered simultaneously to an entire fish population contained in a body of water by spraying, dissolving and/or immersing the vaccine in the water.
- population vaccination methods can be used in various environments such as ponds, aquariums, natural habitat, fish farms and fresh water reservoirs.
- Example 1 Isolation and Characterization of Tilapia Virus
- a cell line was developed from Tilapia fins, and which was used to isolate an RNA virus from fish collected during the mortality events of 2012. The virus was temporarily designated Tilapia Virus - TLV.
- Virus was isolated as follows: Samples from frozen organs originated from sick Tilapia were thawed, pooled together, homogenized, filtered through a 0.2 ⁇ filter and inoculated on naive Tilapia Fin Cells (TFC). TFC infected cultures were incubated at 28°C and monitored daily for cytopathic effect (CPE). Visible CPE was seen 4-7 days post inoculation and included clear plaque formation (Fig. 2). No CPE was evident in mock-infected TFC control cultures. Secondary inoculation of TFC naive cultures with supernatants from TFC cultures exhibiting CPE was repeated for over 20 passages with similar CPE results.
- CPE cytopathic effect
- the Tilapia cell line propagates the isolated virus at high titers. Electron microscopy analysis of infected cell cultures shows virion structures within the cells ( Figure 1). The TLV virus is spherical in shape, and shows variation in size and pleomorphic morphology. In infected cells virus particles appears in cytoplasmic vacuoles, and have an average diameter of ⁇ 65nm.
- SEQ ID NO: 1 The full sequence (with U represented as T) is set out herein as SEQ ID NO: 1 (start and stop codons are predicted at nt 38 and 1595, respectively).
- SEQ ID NO: 2 The 520 amino acid conceptual translation of the sequence (in frame +2) is set out as SEQ ID NO: 2.
- Contig 7 (SEQ ID NO: 3) and its frame 2 translation (SEQ ID NO: 4); Contig 5 (SEQ ID NO: 5), and its phase 6 translation (SEQ ID NO: 6); Contig 6 (SEQ ID NO: 7) and its phase 6 translation (SEQ ID NO: 8): Contig 8 (SEQ ID NO:9) and its phase 6 translation (SEQ ID NO: 10); Contig 14 (SEQ ID NO: 11) and its phase 5 translation (SEQ ID NO: 12); Contig 15 (SEQ ID NO: 13) and its phase 6 translation (SEQ ID NO: 14); Contig 12 (SEQ ID NO: 15) and its phase 5 translation (SEQ ID NO: 16); Contig 16 (SEQ ID NO: 17) and its phase 3 translation (SEQ ID NO: 18); Contig 20 (SEQ ID NO: 19), its phase 1 (SEQ ID NO: 20) and phase 2 (SEQ ID NO: 21) translations; Contig 21 (SEQ ID NO:22) and its phase 5
- the amino acid sequence set forth as SEQ ID NO: 2 resembles the PB1 RNA Polymerase of Orthomyxo virus.
- TREX-MAFFT sequence analysis software a Phylogenic tree was assembled, comparing known Orthomyxo virus PB1 amino acid sequences (such as from influenza virus) to that of TLV. The results of this analysis are presented in Figure 3, which suggests that the isolated TLV may be an emerging pathogen in aquaculture of tilapia species and a new genus within the Orthomyxo viridae.
- This example demonstrates TLV detection in infected cultures or infected organs (liver, spleen, kidney, brain) derived from sick Tilapia fish:
- TLV infection is identified by detection of TLV RNA in an infected sample by PCR.
- Sample RNA is produced from viral-infected TFC or from organs derived from sick Tilapia fish, using Aurum Total RNA Mini kit according to the manufacturer's instructions (BIO-RAD Cat# 732-6820), and cDNA is generated from the isolated RNA using the Reverse Transcriptase Verso cDNA Kit according to manufacturer's instructions (Thermo scientific Cat# AB 1453/A).
- RT-PCR reactions were then carried out according to standard protocols using the produced cDNA as template, and with a set of primers for identifying Contig 4 (SEQ ID NOs 25-26)(as shown in Figure 8).
- Contig 4 contains a putative conserved domain belonging to the Influenza RNA-dependent RNA polymerase subunit PB 1.
- Table 1 is a summary comparison of the 16 observed TLV Contigs. Sucrose gradient purified TLV was sequenced using next generation sequencing technology. Genomic analysis revealed 16 distinct Contigs (at a range of 400-1620bp) which did not resemble known sequences appearing in the GenBank. To determine whether these sequences were in fact associated with TLV, specific primers were designed to amplify each of the sequences and RT-PCR was carried out using the primers sets on templates generated from infected and non-infected TFC. Of the 16 Contigs 12 were shown to be of viral origin, appearing only in infected cultures (see Table 1). The four Contigs which were positive for both infected and non-infected cultures are assumed to be unpublished endogenous Tilapia sequences (in bold).
- Table 1 Summary of RT- PCR results of 16 Contigs assayed with specific primers designed for each assayed with templates from infected and non-infected TFC.
- FIG 7 is an electrophoresis gel showing detection of TLV in infected cultures using Conl9 primers, and which demonstrates that TLV has an RNA genome that does not pass through a DNA stage during its propagation cycle.
- Conl9 was amplified in an RT-PCR reaction only when assayed on infected cultures following a reverse transcriptase reaction (Fig 7 lanel). Samples from non-infected cells and from DNA extracted from infected and non-infected cells assayed with Conl9 primers were negative (Fig 7 lanes 2, 4 and 5).
- Figure 7 also demonstrates that TLV possesses an RNA genome which does not pass through a DNA stage during its life cycle (compare lanes 5, 6, 8, and 9).
- a TLV isolate was continuously passaged on Tilapia fin cells for 20 passages, and subjected to UV irradiation at incremented intensities (Figure 4). At the sub lethal dosage of 6.8mJ/cm 2 , virus clones were picked and propagated as a single viral clone.
- Tilapia Fish were vaccinated with two cloned viruses and a placebo control through immersion for lhour.
- the vaccinated groups were: (1) Placebo control: medium devoid of viral antigen; (2) TLV plO (clone 6) - virus passaged 10 times in culture, UV irradiated and cloned; and (3) TLV p20 (clone 4) - TLVplO passaged 10 times more in culture UV irradiated and cloned.
- Fish were monitored for 35 days for mortality or other adverse events associated with disease (Figure 5).
- TLV p20 (clone 4), also referred to as TLV clone 4, was deposited with the CNCM (Pasteur Institute) on April 1, 2016 as Accession No. CNCM I- 5075. Partial sequence characterization of this clone revealed deletions in at least segments 4 and 5 of the TLV genome (shown here as SEQ ID NOs 49 and 50, respectively). It will be appreciated that mutant- specific portions of these sequences can be used for detection of the attenuated strain, and distinguishing them from the wildtype strain.
- the results of the efficacy challenge are shown in Figure 6.
- the challenged placebo group exhibited a mortality pattern which is evident of TLV infection. Fish became lethargic and went off feed, coloration of fish skin became dark and mortality began at day 12 post- exposure, peaking at 20 days, and reaching 100% mortality during the efficacy trial period.
- the unchallenged placebo group was uneventful and showed no sign of disease.
- Fish vaccinated with TLV plO (clone 6) exhibited a delayed onset of mortality only beginning at day 20 post-challenge, and peaking to 28% mortality.
- Fish vaccinated with TLV p20 (clone 4) showed no sign of disease and were comparable in behavior to the unchallenged placebo group. A mortality level of 2.9% (a single fish) was observed during the observation period.
- TLV p20 (clone4) shows a favorable vaccination profile both for safety and efficacy parameters tested.
- TLV is exposed to 0.2% formaldehyde and passaged until the exposed virus in non-infective.
- the ability of the isolated inactivated strains to confer resistance to TLV infection is then tested on live fish by injection with and without commercial adjuvants. Results are shown in Figure 9.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276873P | 2016-01-10 | 2016-01-10 | |
US201662352570P | 2016-06-21 | 2016-06-21 | |
PCT/IL2017/050027 WO2017118989A1 (en) | 2016-01-10 | 2017-01-10 | Orthomyxo-like virus of tilapia |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3400007A1 true EP3400007A1 (en) | 2018-11-14 |
EP3400007A4 EP3400007A4 (en) | 2019-08-28 |
Family
ID=59274499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17735934.6A Withdrawn EP3400007A4 (en) | 2016-01-10 | 2017-01-10 | Orthomyxo-like virus of tilapia |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3400007A4 (en) |
CN (1) | CN108778324A (en) |
BR (1) | BR112018014042A2 (en) |
CO (1) | CO2018008288A2 (en) |
MX (1) | MX2018008529A (en) |
WO (1) | WO2017118989A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108624718A (en) * | 2018-06-20 | 2018-10-09 | 上海海洋大学 | Constant temperature detects the RPA kits and its primer special and probe of Tilapia mossambica lake virus in real time |
CN112194710A (en) * | 2020-08-19 | 2021-01-08 | 佛山科学技术学院 | Recombinant protein coded by tilapia lake virus S8 gene, antibody prepared from recombinant protein and application of recombinant protein |
NL2028806B1 (en) * | 2021-07-22 | 2022-06-03 | Univ Northwest A&F | Tilv-2 protein or gene encoding tilv-2 protein in preparation of subunit vaccine against tilapia lake virus |
CN113718061B (en) * | 2021-09-30 | 2023-06-09 | 厦门海关技术中心 | Primer set, kit and method for simultaneously detecting double RT-PCR of rochu virus and viral nervous necrosis virus |
CN113755645B (en) * | 2021-09-30 | 2023-06-09 | 厦门海关技术中心 | Fluorescent quantitative RT-PCR primer pair and probe for detecting rochu virus, kit and detection method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL230970A0 (en) * | 2014-02-13 | 2014-09-30 | Univ Ramot | Tilapia lake virus vaccines |
SG10201901053TA (en) * | 2014-12-15 | 2019-03-28 | Univ Columbia | Novel tilapia virus and uses thereof |
-
2017
- 2017-01-10 BR BR112018014042-2A patent/BR112018014042A2/en not_active Application Discontinuation
- 2017-01-10 EP EP17735934.6A patent/EP3400007A4/en not_active Withdrawn
- 2017-01-10 MX MX2018008529A patent/MX2018008529A/en unknown
- 2017-01-10 CN CN201780015550.2A patent/CN108778324A/en active Pending
- 2017-01-10 WO PCT/IL2017/050027 patent/WO2017118989A1/en active Application Filing
-
2018
- 2018-08-06 CO CONC2018/0008288A patent/CO2018008288A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CO2018008288A2 (en) | 2018-08-21 |
CN108778324A (en) | 2018-11-09 |
BR112018014042A2 (en) | 2019-02-12 |
WO2017118989A1 (en) | 2017-07-13 |
MX2018008529A (en) | 2019-06-06 |
EP3400007A4 (en) | 2019-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3400007A1 (en) | Orthomyxo-like virus of tilapia | |
Tuppurainen et al. | The detection of lumpy skin disease virus in samples of experimentally infected cattle using different diagnostic techniques | |
US20090181363A1 (en) | Non-invasive detection of fish viruses by real-time pcr | |
Zahur | Peste des petits ruminants vaccine (Nigerian strain 75/1) confers protection for at least 3 years in sheep and goats | |
Ashmi et al. | Molecular characterization of canine distemper virus from Tamil Nadu, India | |
Şevik et al. | Genetic characterization of peste des petits ruminants virus, Turkey, 2009–2013 | |
Wellenberg et al. | Presence of European bat lyssavirus RNAs in apparently healthy Rousettus aegyptiacus bats | |
Mayahi et al. | Characterization of isolated pigeon paramyxovirus-1 (PMV-1) and its pathogenicity in broiler chickens | |
CN105802921B (en) | Recombinant pseudorabies virus variant strain for expressing classical swine fever virus E2protein and construction method and application thereof | |
US7700326B2 (en) | RT-PCR detection for differential diagnosis of field isolates or lapinized vaccine strain of classical swine fever virus (CSFV) in samples | |
JP6027023B2 (en) | Compositions and methods for identifying and distinguishing viral components of multivalent transport fever vaccines | |
Davidson et al. | Molecular identification of the Marek's disease virus vaccine strain CVI988 in vaccinated chickens | |
Okino et al. | Rapid detection and differentiation of avian infectious bronchitis virus: an application of Mass genotype by melting temperature analysis in RT-qPCR using SYBR Green I | |
Li et al. | Rapid pathotyping of Newcastle disease virus from allantoic fluid and organs of experimentally infected chickens using two novel probes | |
Ghadimipour et al. | Monitoring of newcastle disease virus vaccine strain replication in embryonated chicken eggs by reverse transcription-polymerase chain reaction | |
Dishon et al. | Vaccination against koi herpesvirus disease | |
El-Shazly et al. | Isolation and molecular characterization of newcastle disease virus genotype VI from pigeons in Egypt | |
Mondal et al. | Selection of a suitable viral DNA extraction method for sheeppox virus in cell culture | |
Sohaib et al. | Prevalence of avian influenza virus (H5) in poultry layer flocks in and around Faisalabad, Punjab, Pakistan | |
Gough et al. | Characterization of a herpesvirus isolated from domestic geese in Australia | |
Mahravani et al. | Genetic and antigenic analysis of type O and A FMD viruses isolated in Iran. | |
KR102435209B1 (en) | Composition for simultaneously distinguishing and detecting influenza type A and type B viruses and type 2 severe acute respiratory syndrome coronavirus and detection method using the same | |
Gulyaz et al. | Molecular characterization of contagious ecthyma virus (CEV) isolated from goat and cross-protection studies1 | |
Żmuda et al. | Specific humoral immunity in mink infected with the Aleutian disease virus (AMDV) and vaccinated against distemper. | |
Magouz et al. | Molecular characterization of two selected Pigeon Paramyxovirus-1 isolates reveals two different cleavage site amino acid motifs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180730 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABIC BIOLOGICAL LABORATORIES LTD. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190729 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 7/00 20060101ALI20190723BHEP Ipc: A61P 31/14 20060101ALI20190723BHEP Ipc: A61K 39/12 20060101AFI20190723BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200227 |